Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Margherita Norelli; Barbara Camisa; Giulia Barbiera; Laura Falcone; Ayurzana Purevdorj; Marco Genua; Francesca Sanvito; Maurilio Ponzoni; Claudio Doglioni; Patrizia Cristofori; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Renato Ostuni; Chiara Bonini; Monica Casucci; Attilio Bondanza

doi:10.1038/s41591-018-0036-4

Keywords

NeurotoxicityCytokine release syndromeChimeric antigen receptorMedicineTocilizumabImmunologyCytokineReceptor antagonistMonocyteAnakinraT cellReceptorPharmacologyCancer researchAntagonistImmune systemToxicityInternal medicineDisease

Affiliated Institutions

Related Publications

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp , Michael Kalos , David M. Barrett +10 more

Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whet...

2013 New England Journal of Medicine 3403 citations

Chimeric Antigen Receptor Therapy

Carl H. June , Michel Sadelain

Interview with Dr. Carl June on chimeric antigen receptor therapy. (09:04)Download This review addresses T-cell engineering and synthetic immunity, with a focus on producing dur...

2018 New England Journal of Medicine 2080 citations

Cytokine release syndrome

Alexander Shimabukuro‐Vornhagen , Philipp Gödel , Marion Subklewe +6 more

During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell eng...

2018 Journal for ImmunoTherapy of Cancer 1567 citations

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja , Deepu Madduri , Saad Z. Usmani +33 more

CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation anti...

2021 The Lancet 1466 citations

CAR T cell immunotherapy for human cancer

Carl H. June , Roddy S. O’Connor , Omkar U. Kawalekar +2 more

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The fie...

2018 Science 2861 citations

Publication Info

Year: 2018
Type: article
Volume: 24
Issue: 6
Pages: 739-748
Citations: 1302
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1302

OpenAlex

Cite This

APA Style

                            
                                
                                    Margherita Norelli, 
                                
                                    Barbara Camisa, 
                                
                                    Giulia Barbiera
                                
                                et al.
                            
                            (2018). 
                            Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. 
                            Nature Medicine
                            , 24
                            (6)
                            , 739-748.
                            https://doi.org/10.1038/s41591-018-0036-4
                        

Identifiers

DOI: 10.1038/s41591-018-0036-4